Blue Water Vaccines, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Neil J. Campbell MA, MBA
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 201 East Fifth Street Cincinnati OH United States of America 45202
- IPO Date
- Feb 18, 2022
- CIK
- 0001782107
- Website
- bluewatervaccines.com
- Similar Companies
- Business
- Blue Water Vaccines, Inc. is a biotechnology company specializing in the research, development, and commercialization of vaccines and pharmaceutical products targeting infectious diseases and other medical conditions. The company's main products include vaccine candidates for universal influenza; serotype-independent Streptococcus pneumoniae vaccine aimed at preventing acute otitis media and pneumococcal pneumonia; novel norovirus and rotavirus vaccines based on the licensed S&P nanoparticle virus-like particle platform; and a Chlamydia vaccine candidate developed in collaboration with academic institutions. Blue Water also markets FDA-approved pharmaceutical drugs such as Entadfi, a once-daily capsule combining finasteride and tadalafil for benign prostatic hyperplasia treatment, alongside a portfolio of six FDA-approved drugs including Zontivity (cardiovascular), Otovel and Cetraxal (otic infections), Conjupri (calcium channel blocker), and pain medications Trezix and Nalfon. Recently, Blue Water Vaccines has undergone significant strategic transformation. In 2023, the company expanded its commercial portfolio by acquiring Entadfi from Veru Pharmaceuticals for $100 million, signifying a shift towards a broader pharmaceutical commercial business beyond vaccines. This acquisition was accompanied by a corporate name change to Blue Water Biotech reflecting the expanded focus. However, in a later pivot under new leadership, the company reprioritized its pipeline, discontinuing all vaccine programs and divesting its six FDA-approved drugs acquired earlier, with a new strategic focus on oncology. The CEO transition in 2023 and management overhaul accompanies the pivot, marking a substantial operational change in business direction. Prior to the pivot, Blue Water had formed collaborations with academic institutions such as Cincinnati Children’s Hospital, St. Jude Children’s Research Hospital, and the University of Texas Health Science Center to advance vaccine candidates. Founded in 2015 and headquartered in the United States, Blue Water operates primarily in the biotechnology and pharmaceutical industries, targeting infectious diseases, oncology, and specialty pharmaceutical markets globally, with a focus on vaccine innovation and drug commercialization. The company’s product pipeline and commercial portfolio reflect its evolution from a vaccine-focused biotech to a broader biopharmaceutical entity navigating strategic repositioning as of late 2023 and 2024. This comprehensive profile captures Blue Water Vaccines’ core products and services, recent strategic shifts including acquisitions and divestitures, and operational transformations to reposition itself within the biotech and pharmaceutical landscape.
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
Blue Water Biotech Issues Letter to Shareholders
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
How to Trade Penny Stocks Online: Short Guide
Penny Stocks To Buy After CPI Report? 3 To Watch Today
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022